Skip to main content
RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc. — Investor Relations & Filings

Ticker · RAPT ISIN · US75382E1091 LEI · 549300MB473BIU78ES48 US Manufacturing
Open in API
Filings indexed 534 across all filing types
Latest filing 2021-06-17 Director's Dealing
Country US United States of America
Listing US RAPT

About RAPT Therapeutics, Inc.

https://rapt.com/

RAPT Therapeutics, Inc. is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunologic diseases. The company's scientific approach involves developing therapeutics that intelligently target key drivers of the immune system. Its pipeline includes ozureprubart (RPT904), a long-acting anti-IgE antibody being evaluated in a Phase 2b clinical trial for the treatment of food allergies.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2021-06-17 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 15, 2021, reporting an underwriting agreement for a public offering of common stock by RAPT Therapeutics, Inc. It details the terms of the offering, including the number of shares, price, underwriters, and related legal opinions. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, management discussion, or governance report. The content focuses on a capital raising event through a public offering of shares, which fits the category of Capital/Financing Update. The document length is about 4976 characters, which is sufficient to contain substantive information about the financing event rather than just an announcement or a brief notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-06-16 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and other related disclosures. This type of document is a capital raising filing that updates and supplements a previously filed prospectus. It is not a financial report, earnings release, or management discussion, but rather a financing-related disclosure. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or a brief summary.
2021-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2021-06-16 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering by the company. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other related disclosures typical of a securities offering document. It is not a financial report, earnings release, or management discussion, but rather a capital raising document. The presence of terms like 'prospectus supplement', 'common stock offering', 'underwriting discounts', and references to SEC registration and effective dates confirm this is a capital/financing update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence score.
2021-06-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 14, 2021. It announces positive topline results from a Phase 1b clinical trial and references a press release and an investor presentation as exhibits. The document includes a notice of a conference call and webcast to discuss the trial results. The content is primarily an announcement of events and references to other materials rather than a full financial report or detailed financial statements. The document length is 3551 characters, which is relatively short and consistent with an 8-K current report. The presence of an investor presentation as an exhibit suggests the document is related to investor communication but is not itself the presentation. Given these factors, the document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Investor Presentation itself.
2021-06-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.